"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next year.
Europe’s most valuable company Novo Nordisk reports an uptick in profits as demand for weight-loss drugs continues to grow
August 7, 2024
Novo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise
January 24, 2025
Novo Nordisk’s Wegovy sales jump on international rollouts
The Danish weight loss drug-maker claims "knock-off" treatments are hitting growth.
Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition
The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around…
The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key U.S.…
The medicine developed by the100-year old Danish drugmaker may impact patients' brains in surprising ways
The early data is a boost to the Danish drugmaker's hopes of winning back more market share from Eli Lilly this year in the…
